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Dyslipidaemia
Chronic kidney disease (CKD) is associated with alterations 
in lipoprotein structure and function, including:
• reduced high-density lipoprotein cholesterol 
• increased intermediate-density lipoprotein
• increased proatherogenic lipid particles.
Significance of dyslipidaemia control 
• Successful treatment of dyslipidaemia is known to lower cardio-
vascular disease (CVD) risk and should also retard the decline of 
kidney function.
• Since statins have been shown to decrease urinary protein 
or albumin excretion, they are recommended for CKD with 
proteinuria.
• Remarks on statin use in stages 3 - 5 CKD are given in Table 1.
• Concurrent use of statins and fibrates increases the risk of 
rhabdomyolysis.
Target for low-density lipoprotein cholesterol  
• The Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines recommend the following for dyslipidaemia therapy 
in CKD: in cases of low-density lipoprotein cholesterol (LDL-C) 
<3.5  mmol/L, the first step is lifestyle modification; in cases of 
LDL-C >3.5  mmol/L, drug therapy should be contemplated in 
addition to lifestyle modification, including diet therapy, weight 
control and exercise. 
• It is essential that LDL-C be lowered to ≤1.8 mmol/L.
KDOQI guidelines for cholesterol lowering in CKD 
patients (2013):
• Patients  >50 years of age should receive a statin.
• Patients 18 - 49 years of age should receive a statin if another 
comorbidity is present.
• Kidney transplant recipients should receive a statin. 
Treatment of hyperkalaemia and 
metabolic acidosis 
Hyperkalaemia
• As CKD progresses in stage, acidosis and hyperkalaemia are observed. 
Hyperkalaemia is defined as a serum potassium level ≥5.5 mmol/L. 
Hyperkalaemia >7 mmol/L may potentially cause cardiac arrest; such 
cases should be treated as emergencies.
• If severe hyperkalaemia is observed, despite the absence of 
reduced kidney function, pseudohyperkalaemia, an artefact due to 
haemolysis of the blood specimen, should be considered.
• Hyperkalaemia is a risk factor for arrhythmias. In cases of severe 
hyperkalaemia, emergency levels should be confirmed by ECG 
abnormalities such as tenting T-waves, prolongation of PQ-times, 
followed by disappearance of the P-wave and widening of the QRS 
complex. Patients with life-threatening ECG findings, bradycardia 
and hypotension should be treated promptly, followed by treatment 
in conjunction with a nephrologist.
• Drug-induced hyperkalaemia in CKD is mostly caused by renin-
angiotensin-aldosterone inhibitors such as ACE inhibitors, 
angiotensin II receptor blockers (ARBs) and spironolactone 
or excessive intake of potassium-containing foods. Other 
causes include the administration of β-blockers, digoxin, non-
steroidal anti-inflammatory drugs (NSAIDs), trimethoprim or 
pentamidine.
• CKD caused by diabetic nephropathy may be associated 
with hyporeninaemic hypoaldosteronism, which may cause 
hyperkalaemia despite relatively well-preserved kidney function. 
This is known as type IV renal tubular acidosis.
Emergency treatment 
• The first step is to stabilise the myocardium. The intravenous 
administration of calcium gluconate does not change plasma 
potassium, but transiently improves the ECG. The administration 
of calcium gluconate 20 mL intravenously over 1 minute can 
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be repeated if there is no improvement in the ECG within 3 - 5 
minutes.
• The second step is to shift the potassium from the extracellular 
to the intracellular compartment to try to rapidly decrease the 
serum potassium level. This can be done in three different 
ways: 
• Intravenous insulin combined with glucose. Administer 10 U 
short-acting insulin combined with 50 mL of 50% dextrose as 
a bolus, followed by an intravenous infusion of 5% dextrose to 
prevent hypoglycaemia.
• β2-agonist. Administer 20  mg salbutamol, a β2-agonist, by 
inhalation over 10 minutes, with onset of action approximately 
30 minutes. (This is not usually required.) 
• Sodium bicarbonate in CKD patients who are not yet 
on dialysis. Bicarbonate administration can lower serum 
potassium by enhancing renal potassium excretion. The effect 
is very slow and not of use in an acute situation unless the 
patient has severe metabolic acidosis that needs bicarbonate 
treatment.
• Once the previous temporary measures have been performed, 
further interventions are undertaken to remove potassium from 
the body.
• Loop diuretics are only successful in patients with adequate 
kidney function.
• The resin exchanger sodium polystyrene sulphonate (Kexelate) 
removes potassium from the blood into the gut in exchange for 
an equal amount of sodium. It is slow acting and the plasma 
potassium only starts decreasing within 1 - 2 hours. It can be given 
orally or as a retention enema. The amount given varies from 30 g 
to 60 g. This can be repeated, but tends to cause constipation.
• Haemodialysis is the treatment of choice for patients with advanced 
CKD and severe hyperkalaemia.
Prevention 
• Dietary counselling on potassium restriction.
• Avoid medications that interfere with renal excretion of potassium, 
e.g. potassium-sparing diuretics, NSAIDs, ACE inhibitors, ARBs.
• Avoid drugs that interfere with potassium shifts from the intracellular 
to the extracellular compartments, e.g. non-selective β-blockers.
• In selected patients with sufficient residual kidney function treatment 
with a loop diuretic may be used to stimulate urinary potassium 
excretion.
Metabolic acidosis
Metabolic acidosis is characterised by:
• low arterial blood pH (acidaemia) (<7.35)
• reduced serum HCO3-  concentration
• decreased pCO2 (from respiratory compensation).
Systemic effects 
Metabolic acidosis may lead to a variety of changes in tissues and 
organs, e.g.:
• cardiovascular changes such as tachycardia, bradycardia, 
hypotension and cardiac failure
• life-threatening hyperkalaemia
• nausea, vomiting and abdominal pain
• confusion, with depression of the central nervous system.
The associated symptoms and signs will depend on the rate and 
magnitude of fall in the pH and of the underlying pathology.
Table 1. Drugs for dyslipidaemia available in South Africa and cautionary remarks regarding their use in CKD
Class Generic name Characteristics Use in low GFR
3-hydroxy-3-methyl-
glutaryl-CoA reductase
enzyme inhibitors
(statins)
 Pravastatin
 Simvastatin
 Fluvastatin
 Atorvastatin
 Rosuvastatin
Inhibits cholesterol production 
in the liver 
Very effective to decrease TC, 
LDL-C
Adverse reaction: liver damage, 
rhabdomyolysis
Prolongs QT-interval on ECG
Main excretory route is the bile duct, i.e. it can be used 
in kidney damage (pravastatin is excreted mainly in the 
urine)
Rhabdomyolysis may occur, although there is a low 
incidence in CKD. In stages 3 and higher CKD, careful 
follow-up is necessary
Cyclosporine, which is often used in resistant 
nephrotic syndrome, may have adverse effects if used 
simultaneously
Anion exchange resins Cholestyramine
Colestimide
Inhibits bile acid circulation 
(intestine-liver)
Lowers TC, LDL-C
No problems
Fibrates Bezafibrate
Fenofibrate
Lowers TG (very effective)
Increases HDL-C
Rhabdomyolysis
Do not use with statins
Do not use bezafibrate or fenofibrate in kidney failure or 
dialysis patients
Do not use for stages 4 and 5 CKD 
Nicotinic acids Lowers TG
Lowers Lp (a)
Rash on face
No problems
Others Eicosapentaenoic acid 
Ezetimibe
Lowers TG
Antiplatelet function: anti-
atherosclerosis
Prevents absorption of 
cholesterol
No problems
TC = total cholesterol; TG = triglyceride; HDL-C = high-density lipoprotein cholesterol; LPL = lipoprotein lipase; Lp (a) = lipoprotein (a); GFR = glomerular filtration rate; 
ECG = electrocardiogram.
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Uraemic acidosis
Metabolic acidosis occurs in renal failure owing to a decreased ability 
to excrete H+ or an inability to produce ammonia.
In the early stages of CKD (GFR <40 mL/min), metabolic acidosis 
with a normal anion gap (AG) may become evident. As CKD 
progresses (GFR <20  mL/min), a high AG metabolic acidosis may 
result.
In advanced CKD, an increased AG is typical owing to the presence 
of retained acids such as sulphates, phosphates, urate and hippurate. 
Treatment principles 
Patients with metabolic acidosis are often very ill and their condition 
tends to deteriorate rapidly.
The routine administration of sodium bicarbonate is controversial, 
although it needs to be done to correct severe acidosis.
The potential complications of sodium bicarbonate administration 
include volume overload, especially in patients with renal or cardiac 
function impairment, hypernatraemia, hypokalaemia, hypocalcaemia 
and alkalosis.
The amount of bicarbonate required (mmol) can be estimated as 
follows:
 target plasma HCO3- (mmol/L) − current plasma HCO3- (mmol/L) 
× 40% body weight (kg).
Anaemia in CKD
Anaemia is the most common complication of CKD and is associated 
with greatly reduced quality of life. Successful treatment of anaemia 
in renal disease may reduce the decline of kidney function. The 
target haemoglobin levels are 10 - 12 g/dL when treating anaemia in 
CKD. The treatment is costly and therefore rational consideration is 
mandatory.
Renal anaemia 
Renal anaemia is typically normochromic normocytic. It is caused 
mainly by the impaired production of erythropoietin by the kidney 
and partly by uraemic toxins. Other causes that may play a role in 
CKD, especially in dialysis patients, are:
• erythropoietin resistance (most significant)
• bone marrow toxins (none has been isolated yet)
• bone marrow fibrosis, secondary to hyperparathyroidism
• ongoing inflammatory processes, e.g. untreated infections
• haematinic deficiency (iron, folate and vitamin B12)
• increased red cell destruction
• abnormal red cell membranes, causing increased osmotic fragility
• increased blood loss from occult gastrointestinal bleeding and 
blood sampling and during haemodialysis
• ACE inhibition.
Erythropoietin is a glycoprotein hormone that stimulates red cell 
production by binding to erythropoietin receptors, located on early 
erythroid progenitor cells in the bone marrow. 
The binding of erythropoietin to these progenitor cells saves them 
from apoptosis and therefore permits cell division and maturation 
into red cells. In CKD, the erythropoietin levels may be normal, but 
inadequate for the degree of anaemia. The mechanisms impairing 
erythropoietin production in diseased kidneys remain poorly 
understood. Inhibition of erythropoiesis by uraemic inhibitors is also 
possible and may contribute greatly to the anaemia of CKD; such 
factors have not been identified. Dialysis can improve renal anaemia 
and the efficacy of erythropoietin-stimulating agents. Patients with 
renal disease may develop chronic infections and other chronic 
diseases. Chronic disease contributes to anaemia in such cases. The 
anaemia of chronic disease is mediated by inflammatory cytokines 
through the inhibition of erythropoietin production and efficacy and 
reduced iron availability. 
Hepcidin is the key mediator of iron metabolism. In inflammatory 
states hepcidin blocks iron absorption in the gut and promotes iron 
sequestration in macrophages. 
Other causes  
Anaemia associated with CKD is most likely renal anaemia; however, 
the differential  for other diseases must be considered true for stages 
1 - 3 CKD.
The evaluation of anaemia in CKD patients should include a 
complete blood count with red cell indices (mean corpuscular 
haemoglobin concentration, mean corpuscular volume). Renal 
anaemia is usually normochromic and normocytic. Vitamin 
B12 and folate deficiency may lead to macrocytosis, while iron 
deficiency or inherited disorders of haemoglobin may produce 
microcytosis. Iron studies should be performed to assess the 
level of iron in tissue stores or the adequacy of iron supply for 
erythropoiesis. 
Anaemia may signify the presence of malnutrition or systemic 
illness. It is an independent risk factor for hospitalisation, CVD and 
mortality. ACE inhibitors can exacerbate anaemia. 
Treatment of anaemia protects the heart
Anaemia exacerbates heart failure. Treatment of anaemia is beneficial 
for life expectancy and can also improve the prognosis of CVD. The 
quality of life is improved for those with a haemoglobin level within 
the target range.
Target level of haemoglobin
The Kidney Disease Improving Global Outcome (KDIGO) 
guidelines state that the haemoglobin level should range from 
10.0 g/dL to 12 g/dL in CKD patients on dialysis. Pre-dialysis 
levels should be at 10 g/dL. 
Role-sharing between nephrologists and primary care 
physicians 
Early referral to a nephrologist is advisable. Once the treatment 
strategy has been decided, nephrologists and primary care physicians 
continue management in partnership.
Evaluation of iron deficiency  
Evaluation of the iron deficit and correct iron supply is important 
in the treatment of anaemia. Anaemia may improve with the 
administration of iron supplements, even when the patient is not 
apparently iron deficient, as the use of recombinant erythropoietin 
may cause relative iron deficiency.
The KDOQI guidelines for recombinant human erythropoietin in 
CKD are:
• serum ferritin >100 ng/mL before dialysis
• serum ferritin >200 ng/mL in dialysis patients
• transferrin saturation >20%.
Iron can be given either intravenously or orally. Intravenous iron 
is more efficacious, especially for dialysis patients and those on 
erythropoietin treatment.
Use of exogenous erythropoietins
There are currently a number of erythropoietin-stimulating agents 
available, including older, shorter-acting drugs and new, longer-acting 
ones. The appropriate agent and dose depend on a number of factors, 
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including cost, efficacy and convenience. As these drugs are expensive 
and have side-effects, their management is best left to a nephrologist.
Bone and mineral disorders 
Hyperphosphataemia is the key abnormality that sets off a 
cascade of metabolic events, resulting in bone mineral density 
of CKD.
Phosphate is retained as renal function deteriorates – much the 
same as creatinine is retained. This retention becomes obvious as 
stage 3b CKD is reached. It will progressively worsen as end-stage is 
approached and must be lowered to within normal limits. 
A high phosphate diet stimulates osteocytes to produce fibroblast 
growth factor 23 which, in turn, inhibits the hydroxylation of 
vitamin D to active 1,25 vitamin D3. Without vitamin D3, calcium 
absorption and bone remodelling are decreased. The resultant 
hypocalcaemia is a major stimulus for parathyroid hormone 
(PTH) release, with the consequent development of renal bone 
disease. Serum alkaline phosphatase is a marker of increased bone 
turnover. Therefore, high blood levels show PTH activity. 
Of note, both hyperphosphataemia and vitamin D3 deficiency result 
in increased PTH secretion.
Initially the stimulus for PTH secretion may be controlled 
by increasing the serum calcium, reducing the phosphate 
levels in the blood and prescribing vitamin D3. This is the 
secondary hyper parathyroidism stage (Table 2). However, 
with time and uncontrolled, prolonged stimulation of PTH 
secretion, the parathyroid hormones become autonomous and 
the stage of autonomous hyper para thyroidism is reached 
(Table 3). Parathyroidectomy may now be necessary or expensive 
calcimimetic drugs must be administered to try to restore the 
disordered metabolic environment.  
There is uncertainty about the interpretation of vitamin D3 level 
measurements. If they are to be measured, then 25-OH-vitamin D3 
levels are recommended for assessment. 
Therapy
The steps for therapy are shown in Table 4. Non-calcium-containing 
phosphate binders are recommended when there is significant 
metastatic calcification and/or when hypercalcaemia is present. 
Calcimimetics, which sensitise the parathyroid glands to serum 
calcium, are useful to prescribe in hyperparathyroidism when the serum 
PTH levels are high (2 - 9 times above the normal range – check with the 
laboratory for normal ranges). They have a role to play in diminishing 
PTH levels in any of the clinical situations that occur in CKD. 
Follow-up blood measurements
These are given in Table 5. 
These follow-up times are guidelines only and the tests should be 
performed more frequently if there are significant abnormalities.
Special points to note
• Involve a nephrologist early in the course of CKD.
• Avoid over-suppression of the parathyroid glands, as this will lead 
to dynamic bone disease. 
• The exact PTH level at which secondary and autonomous 
hyperparathyroidism is diagnosed is uncertain, because of vary-
ing assays. The biochemistry, as outlined above (together with 
radiographs of bones), must then be used to assist in the diagnosis. 
• Be aware of trends in serum alkaline phosphatase levels; the level may be 
in the normal range but may have doubled from the previous reading. 
• Osteoporosis accompanies bone disease that occurs in CKD. 
Bisphosphonates must not be used in stages 3 - 5 CKD patients.
Table 2. Diagnosis of secondary hyperparathyroidism*
Serum biochemistry Normal range
Calcium Below or low normal range
Phosphate High 
*PTH 2 - 9 times the normal range (check with the laboratory which assay and normal range) 
and low vitamin D3 levels: measure 25-OH-vitamin D3.
Table 3. Autonomous hyperparathyroidism*
Serum biochemistry Normal range
Calcium Higher or high normal range
Phosphate High 
* PTH >2 - 9 times the normal range (check with the laboratory which assay and 
normal range).
Table 4. Steps for therapy
Steps Stages 3 - 4 CKD Stages 5 - 5d CKD
Lower the 
serum 
phosphate 
Calcium carbonate or 
non-calcium-containing 
phosphate binders, e.g. 
lanthanum carbonate or 
sevelamer carbonate
Calcium carbonate or 
non-calcium-containing 
phosphate binders, e.g. 
lanthanum carbonate or 
sevelamer carbonate
Increase 
the serum 
calcium
First administer calcium 
carbonate, then vitamin D3
First administer calcium 
carbonate, then vitamin D3 
Table 5. Follow-up blood measurements
Stage CKD 3-monthly 6-monthly
3 - Calcium and phosphate 
levels
4 Calcium, phosphate and 
alkaline phosphatase levels 
 PTH levels
 25-OH-vitamin D3
5 Calcium, phosphate and 
alkaline phosphatase levels
PTH levels
25-OH-vitamin D3
